NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Entos Pharmaceuticals

Entos Pharmaceuticals

Private
EdmontonHealthcare & Life Scienceshttps://entospharma.com/

Last Round

Grant

Aug 1, 2025

Total Funding Raised

$126.85M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Entos Pharmaceuticals is a biotechnology company developing genetic medicines using its proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Revenue Share

AI Layer

Application

Keywords

drug delivery platformgenetic medicinenucleic acid deliveryproteo-lipid vehiclesPLVgene therapynon-viral deliverybiotech platformdrug discoveryprecision medicinebiotech licensingdrug delivery techgenetic payloadbiomanufacturingAI drug design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Entos Pharmaceuticals Comparables

Compare Entos Pharmaceuticals with similar companies based on industry and business-model similarity.

Entos Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NanoVation Therapeutics
89%
Acuitas Therapeutics
87%
Genevant Sciences
87%

Entos Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 1, 2025
VC RoundMay 22, 2025
GrantMar 11, 2025
GrantFeb 5, 2025
GrantOct 7, 2023
Grant
Oct 1, 2022

Key People

Founding team and executive leadership

John Lewis

Founder, CEO

Founding Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2026

    Developing a curative therapy for LMNA-Related Congenital Muscular Dystrophy.

  • Apr 20, 2026

    Partnered with L-CMD Research Foundation to develop curative therapy.

Entos Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Entos Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Entos Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersEdmonton
Employee Range35
Year Founded2016
Last FundingAug 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.